Business
Provisional ethics approval for human study
Provisional ethics approval for human study.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 9451U SkinBioTherapeutics PLC 18 July 2018 \n\nSkinBioTherapeutics plc\n \nSkinBioTherapeutics receives provisional ethics approval for human study\n \nManchester, UK - 18 July 2018 - SkinBioTherapeutics plc (AIM: SBTX, the \"Company\"), a life sciences company focused on skin health, announces that it has received provisional ethics approval for its human study scheduled to start later this year. \n \nFull approval will be granted on completion of procedural amendments to the study paperwork which are underway. \n \nThe human study, scheduled for September 2018, will be conducted on 120 female volunteers with self-assessed 'dry skin' over a six week period. The study is designed to test whether the positive impact of the SkinBiotix® technology on the skin's barrier function, which has been demonstrated in laboratory studies, is replicated with human volunteers. Measurements will be taken to assess skin dryness, skin hydration and the skin barrier function. \n\nDr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:\n\"Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence. The procedural amendments we need to make to the paperwork are straightforward and consequently we remain on track to commence the human study in September.\" \n \nThe information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n-Ends-\n \nFor more information, please contact: \n \n\n\n\n\nSkinBioTherapeutics plc\nDr. Cath O'Neill, CEO\nDoug Quinn, CFO \n \n\n\nTel: +44 (0) 161 468 2760\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\nTony Rawlinson / Richard Nash\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nTurner Pope Investments (Joint Broker)\nBen Turner / James Pope\n \nNorthland Capital Partners (Joint Broker)\nJohn Howes / Tom Price\n \n\n\nTel: +44 (0) 20 3621 4120\n \n \nTel: +44 (0) 20 3861 6625\n\n\n\n\nInstinctif Partners (Media Relations)\nMelanie Toyne-Sewell / Deborah Bell \n\n\nTel...